These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 1569445

  • 1. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC.
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S.
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [Abstract] [Full Text] [Related]

  • 3. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD, Burnett LS, Jones HW, Grosh WW, Johnson DH, Greco FA.
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [Abstract] [Full Text] [Related]

  • 4. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.
    Cancer; 1998 Nov 01; 83(9):1980-8. PubMed ID: 9806657
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 6. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M, Mosconi AM, Gori S, Belsanti V, Basurto C, De Angelis V, Giansanti M, Tonato M.
    Am J Clin Oncol; 1997 Oct 15; 20(5):522-6. PubMed ID: 9345342
    [Abstract] [Full Text] [Related]

  • 7. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
    Kohn EC, Sarosy GA, Davis P, Christian M, Link CE, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A, Reed E.
    Gynecol Oncol; 1996 Aug 15; 62(2):181-91. PubMed ID: 8751547
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study.
    Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE.
    J Clin Oncol; 1993 Mar 15; 11(3):440-8. PubMed ID: 8445418
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gynecological malignancies.
    Schaebler DL, Schilder RJ, Young RC.
    Cancer Chemother Biol Response Modif; 1996 Mar 15; 16():564-91. PubMed ID: 8639401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE.
    Eur J Gynaecol Oncol; 1998 Mar 15; 19(1):5-10. PubMed ID: 9476049
    [Abstract] [Full Text] [Related]

  • 15. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F, Schneider J, Markman M, Reichman BS, Venkatraman E, Barakat R, Almadrones L, Spriggs D.
    Gynecol Oncol; 1997 Oct 15; 67(1):39-45. PubMed ID: 9345354
    [Abstract] [Full Text] [Related]

  • 16. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH, Kong BH, Zhang YZ, Yang XS, Wang LJ, Su SL, Jiang J, Cui BX, Wang B.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct 15; 42(10):683-7. PubMed ID: 18241544
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G.
    J Clin Oncol; 1992 May 15; 10(5):718-26. PubMed ID: 1569444
    [Abstract] [Full Text] [Related]

  • 18. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M.
    N Engl J Med; 1996 Jan 04; 334(1):1-6. PubMed ID: 7494563
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L.
    J Clin Oncol; 1986 Jun 04; 4(6):965-71. PubMed ID: 3519886
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
    Zambetti M, Gianni L, Di Re F, Spatti G, Fontanelli R, Escobedo A, De Palo G, Bonadonna G.
    Am J Clin Oncol; 1990 Jun 04; 13(3):199-203. PubMed ID: 2161174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.